---
schema_version: "secwatch.filing_event.v1"
accession: "0001641489-25-000058"
form_type: "8-K"
ticker: "VTVT"
cik: "0001641489"
company_name: "vTv Therapeutics Inc."
filed_at: "2025-11-06T23:59:59+00:00"
generated_at: "2026-05-16T23:44:21.123612+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# vTv Therapeutics Q3 net loss $8.7M; Phase 3 CATT1 data expected H2 2026

## Summary
- Net loss $8.7M ($1.08 per share) vs $4.8M loss ($0.88) in Q3 2024.
- Cash $98.5M at Sept 30, 2025, up from $36.7M at Dec 31, 2024, after $80M private placement.
- First patient randomized in Phase 3 CATT1 trial of cadisegliatin; topline data H2 2026.
- U.S. patent allowed for crystalline salt forms of cadisegliatin; exclusivity through 2041.
- R&D expenses $7.0M, more than double Q3 2024, due to cadisegliatin spend and milestone accrual.

## SEC filing metadata
- accession: 0001641489-25-000058
- form_type: 8-K
- ticker: VTVT
- cik: 0001641489
- company_name: vTv Therapeutics Inc.
- filed_at: 2025-11-06T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/0001641489-25-000058-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1641489/000164148925000058/vtvt-20251106.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001641489-25-000058
- JSON: https://secwatch.observer/filing/0001641489-25-000058.json
- Plain text: https://secwatch.observer/filing/0001641489-25-000058.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.